Obseva SANASDAQ:OBSVNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2101/ 20
- Ask / Lots0.2148/ 10
- Open / Previous Close0.0000 / 0.2100
- Day Range---
- 52 Week Range
- Volume1,350
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OBSV |
|---|---|---|
| 09:32 ET | 10739 | 0.2125 |
| 09:33 ET | 11963 | 0.21 |
| 09:35 ET | 2603 | 0.2129 |
| 09:39 ET | 2500 | 0.211479 |
| 09:42 ET | 7153 | 0.2131 |
| 09:44 ET | 450 | 0.2129 |
| 09:46 ET | 711 | 0.2105 |
| 09:53 ET | 2737 | 0.21 |
| 09:55 ET | 5722 | 0.2095 |
| 10:00 ET | 1200 | 0.21 |
| 10:02 ET | 154583 | 0.2041 |
| 10:04 ET | 310 | 0.20295 |
| 10:06 ET | 11750 | 0.205 |
| 10:09 ET | 499 | 0.203 |
| 10:11 ET | 1418 | 0.20301 |
| 10:13 ET | 1036 | 0.203101 |
| 10:15 ET | 3054 | 0.209199 |
| 10:18 ET | 500 | 0.2065 |
| 10:26 ET | 186 | 0.2065 |
| 10:27 ET | 240 | 0.2051 |
| 10:31 ET | 1134 | 0.2096 |
| 10:40 ET | 1050 | 0.2095 |
| 10:42 ET | 5000 | 0.209599 |
| 10:44 ET | 12200 | 0.2096 |
| 10:45 ET | 1075 | 0.2096 |
| 10:47 ET | 400 | 0.206601 |
| 10:49 ET | 8050 | 0.2096 |
| 10:54 ET | 1700 | 0.2067 |
| 11:00 ET | 400 | 0.207066 |
| 11:02 ET | 600 | 0.2067 |
| 11:09 ET | 300 | 0.2081 |
| 11:21 ET | 100 | 0.2096 |
| 11:25 ET | 100 | 0.2081 |
| 11:27 ET | 1050 | 0.2081 |
| 11:30 ET | 236 | 0.209599 |
| 11:32 ET | 400 | 0.2067 |
| 11:38 ET | 100 | 0.2096 |
| 11:39 ET | 3000 | 0.2096 |
| 11:50 ET | 100 | 0.2093 |
| 11:54 ET | 886 | 0.2095 |
| 11:56 ET | 2532 | 0.2096 |
| 11:57 ET | 438 | 0.2096 |
| 12:01 ET | 4157 | 0.20935 |
| 12:08 ET | 400 | 0.2095 |
| 12:12 ET | 1100 | 0.2095 |
| 12:14 ET | 14846 | 0.2096 |
| 12:15 ET | 549 | 0.2097 |
| 12:28 ET | 3769 | 0.2098 |
| 12:30 ET | 97703 | 0.2092 |
| 12:32 ET | 2000 | 0.2091 |
| 12:37 ET | 120 | 0.2089 |
| 12:50 ET | 333 | 0.209 |
| 12:55 ET | 10000 | 0.2088 |
| 01:09 ET | 1000 | 0.2099 |
| 01:15 ET | 5000 | 0.2082 |
| 01:18 ET | 1000 | 0.2066 |
| 01:33 ET | 1545 | 0.21 |
| 01:36 ET | 462 | 0.21 |
| 01:40 ET | 500 | 0.2092 |
| 01:42 ET | 496 | 0.2096 |
| 01:44 ET | 189 | 0.20932 |
| 01:45 ET | 2000 | 0.2092 |
| 01:47 ET | 200 | 0.2096 |
| 01:51 ET | 390 | 0.21 |
| 01:56 ET | 200 | 0.20955 |
| 02:00 ET | 700 | 0.2091 |
| 02:02 ET | 6122 | 0.20955 |
| 02:05 ET | 300 | 0.2099 |
| 02:07 ET | 712 | 0.21 |
| 02:12 ET | 100 | 0.2092 |
| 02:16 ET | 300 | 0.2092 |
| 02:32 ET | 1000 | 0.2095 |
| 02:34 ET | 2100 | 0.2092 |
| 02:38 ET | 250 | 0.209248 |
| 02:39 ET | 7359 | 0.2092 |
| 02:41 ET | 400 | 0.209243 |
| 02:45 ET | 181 | 0.20755 |
| 02:48 ET | 2000 | 0.20755 |
| 02:56 ET | 10100 | 0.21 |
| 03:12 ET | 200 | 0.209999 |
| 03:14 ET | 450 | 0.20755 |
| 03:21 ET | 41914 | 0.21 |
| 03:24 ET | 5857 | 0.21 |
| 03:28 ET | 800 | 0.21 |
| 03:30 ET | 1777 | 0.21 |
| 03:32 ET | 2000 | 0.2091 |
| 03:39 ET | 2922 | 0.2127 |
| 03:46 ET | 1735 | 0.2091 |
| 03:48 ET | 3000 | 0.2051 |
| 03:51 ET | 1960 | 0.2091 |
| 03:57 ET | 100 | 0.21 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Obseva SA | 21.8M | -0.2x | --- |
Emmaus Life Sciences Inc | 20.1M | -1.1x | --- |
Finch Therapeutics Group Inc | 24.0M | -0.2x | --- |
Aeglea Bio Therapeutics Inc | 30.8M | -0.4x | --- |
Landos Biopharma Inc | 15.6M | -0.3x | --- |
Codiak BioSciences, Inc. | 27.4M | -1.1x | --- |
Company Information
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Contact Information
- Headquarters
- Chemin des Aulx 12PLAN-LES-OUATES, Switzerland 1228
- Phone
- ---
- Fax
- ---
Executives
- Independent Director
- Frank Verwiel
- Chief Executive Officer, Director
- Brian O'Callaghan
- Chief Financial Officer
- Will Brown
- Chief Administrative Officer
- Fabien De Ladonchamps
- Chief Scientific Officer, Head of Research and Development
- Jean-Pierre Gotteland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.8M |
|---|---|
Revenue (TTM) | $8.6M |
Shares Outstanding | 104.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-0.92 |
Book Value | $0.40 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 2.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -640.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
